Daniel Omstead - Tekla Life President Trustee
| XHQLX Fund | USD 15.32 0.01 0.07% |
Dr. Daniel R. Omstead Ph.D. is a President and Trustee of HQ Life Sciences Investors. Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC, a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQH, HQL and THQ and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restrictedventure portfolios within HQH, HQL and THQ. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including IlluminOss Medical, Inc., Magellan Diagnostics, Inc., Dynex Corporationrationration, Insightra Medical, Inc., Neurovance, Inc., EBI Life Sciences, Inc. and Euthymics Biosciences, Inc. Dr. Omstead is also an observer of the Board of Directors of AlterG, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies
| Age | 63 |
| Tenure | 21 years |
Daniel Omstead Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Omstead against Tekla Life mutual fund is an integral part of due diligence when investing in Tekla Life. Daniel Omstead insider activity provides valuable insight into whether Tekla Life is net buyers or sellers over its current business cycle. Note, Tekla Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tekla Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Omstead over a month ago Disposition of 44064 shares by Daniel Omstead of Tekla Life at 19.75 subject to Rule 16b-3 | ||
Daniel Omstead over six months ago Purchase by Daniel Omstead of 10096 shares of Tekla Life | ||
Daniel Omstead over six months ago Purchase by Daniel Omstead of 9500 shares of Tekla Healthcare | ||
Daniel Omstead over six months ago Purchase by Daniel Omstead of 12000 shares of Tekla Life |
Tekla Life Sciences Leadership Team
Elected by the shareholders, the Tekla Life's board of directors comprises two types of representatives: Tekla Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Life's management team and ensure that shareholders' interests are well served. Tekla Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Reardon, Independent Trustee | ||
| Michael Bonney, Independent Trustee | ||
| Oleg Pohotsky, Independent Trustee | ||
| Lucinda Stebbins, Independent Trustee | ||
| Daniel Omstead, President Trustee | ||
| Uwe Reinhardt, Independent Trustee | ||
| Rakesh Jain, Independent Trustee |
Tekla Fund Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right mutual fund is not an easy task. Is Tekla Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tekla Life in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tekla Life's short interest history, or implied volatility extrapolated from Tekla Life options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any mutual fund could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.